https://scholars.lib.ntu.edu.tw/handle/123456789/629212
Title: | Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma | Authors: | RUBY YUN-JU HUANG Huang, Kuan-Ju Chen, Ko-Chen Hsiao, Sheng-Mou Tan, Tuan Zea CHIN-JUI WU Hsu, Ching WEN-CHUN CHANG Pan, Chen-Yu BOR-CHING SHEU LIN-HUNG WEI |
Keywords: | bevacizumab; immune profiling; ovarian clear cell carcinoma | Issue Date: | 15-May-2023 | Publisher: | WILEY | Journal Volume: | 152 | Journal Issue: | 10 | Source: | International journal of cancer | Abstract: | Ovarian clear cell carcinoma (OCCC) is a distinct histotype of ovarian cancer, which usually presages a worse prognosis upon recurrence. Identifying patients at risk for relapse is an unmet need to improve outcomes. A retrospective cohort analysis of 195 early-stage OCCC patients diagnosed between January 2011 and December 2019 at National Taiwan University Hospital was conducted to identify prognostic factors for recurrence, progression-free survival (PFS) and overall survival (OS). Molecular profiling of tumors was performed in a case-controlled cohort matched for adjuvant therapy for biomarker discovery. Multivariate Cox proportional hazard model revealed that paclitaxel-based chemotherapy was associated with better PFS than nonpaclitaxel chemotherapy (HR = 0.19, P = .006). The addition of bevacizumab was associated with better PFS, compared to no bevacizumab (HR = 0.09, P = .02). Neither showed significant improvement in OS. Recurrence is associated with an Immune-Hot tumor feature (P = .03), the CTLA-4-high subtype (P = .01) and increased infiltration of immune cells in general. The Immune-Hot feature (HR = 3.39, P = .005) and the CTLA-4-high subtype (HR = 2.13, P = .059) were associated with worse PFS. Immune-Hot tumor features could prognosticate recurrence in early-stage OCCC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/629212 | ISSN: | 0020-7136 | DOI: | 10.1002/ijc.34428 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.